Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
Auto-generated profile, based on publicly available information
Xijun Liu
Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
The change of oligosaccharide structure has been revealed to be crucial for glycoproteins' biological functions and cell biological characteristics. N‐acetylglucosaminy transferase V (GnT‐V), a key enzyme catalysing the reaction of adding β1, 6‐N‐acetylglucosamine (GlcNAc) on asparagine‐linked oligosaccharides of cell proteins, has been implicated to a metastastic‐promoting oncoprotein in some carcinomas. However, this correlation might not be subjected to all types of cancers, for example, in non‐small cell lung cancers, low level of GnT‐V expression is associated with relatively short survival time and poor prognosis. To explain the role of GnT‐V in lung cancer progression, we studied the association of GnT‐V expression with lung cancer EMT behaviour. We found that GnT‐V expression was correlated with epithelial marker positively and mesenchymal marker negatively. GnT‐V levels, as well as β1,6‐GlcNAc branched N‐glycans, were strongly reduced in TGF‐β1‐induced EMT of human lung adenocarcinoma A549 cells. Further studies showed that suppression of β1,6‐GlcNAc branched N‐glycans by inhibitor or GnT‐V silencing in A549 cells could promote TGF‐β1‐induced EMT‐like changes, cell migration and invasion. Meanwhile, overexpression of GnT‐V impaired TGF‐β1‐induced EMT, migration and invasion. It suggests that GnT‐V suppresses the EMT process of lung cancer cells through inhibiting the TGF‐β/Smad signalling and its downstream transcription factors in a GnT‐V catalytic activity–dependent manner. Taken together, the present study reveals a novel mechanism of GnT‐V as a suppressor of both EMT and invasion in human lung cancer cells, which may be useful for fully understanding N‐glycan's biological roles in lung cancer progression.
Differentiation therapy has been shown effective in treatment of several types of cancer cells and may prove to be effective in treatment of glioblastoma multiforme, the most common and most aggressive primary brain tumor. Although extensively used as a reagent to inhibit protein synthesis in mammalian cells, whether cycloheximide treatment leads to glioma cell differentiation has not been reported.
Nucleophosmin (NPM1/B23) and the activating transcription factor 5 (ATF5) are both known to subject to cell type-dependent regulation. NPM1 is expressed weakly in hepatocytes and highly expressed in hepatocellular carcinomas (HCC) with a clear correlation between enhanced NPM1 expression and increased tumor grading and poor prognosis, whereas in contrast, ATF5 is expressed abundantly in hepatocytes and down-regulated in HCC. Re-expression of ATF5 in HCC inhibits cell proliferation. We report here that using an unbiased approach, tandem affinity purification (TAP) followed with mass spectrometry (MS), we identified NPM1 as a novel ATF5-interacting protein. Unlike many other NPM1-interacting proteins that interact with the N-terminal oligomerization domain of NPM1, ATF5 binds via its basic leucine zipper to the C-terminal region of NPM1 where its nucleolar localization signal is located. NPM1 association with ATF5, whose staining patterns partially overlap in the nucleoli, promotes ATF5 protein degradation through proteasome-dependent and caspase-dependent pathways. NPM1-c, a mutant NPM1 that is defective in nucleolar localization, failed to stimulate ATF5 polyubiquitination and was unable to down-regulate ATF5. NPM1 interaction with ATF5 displaces HSP70, a known ATF5-interacting protein, from ATF5 protein complexes and antagonizes its role in stabilization of ATF5 protein. NPM1-promoted ATF5 down-regulation diminished ATF5-mediated repression of cAMP-responsive element-dependent gene transcription and abrogates ATF5-induced G2/M cell cycle blockade and inhibition of cell proliferation in HCC cells. Our study establishes a mechanistic link between elevated NPM1 expression and depressed ATF5 in HCC and suggests that regulation of ATF5 by NPM1 plays an important role in the proliferation and survival of HCC.
Generally, most of ovarian cancer cannot be detected until large scale and remote metastasis occurs, which is the major cause of high mortality in ovarian cancer. Therefore, it is urgent to discover metastasis-related biomarkers for the detection of ovarian cancer in its occult metastasis stage. Altered glycosylation is a universal feature of malignancy and certain types of glycan structures are well-known markers for tumor progressions. Thus, this study aimed to reveal specific changes of N-glycans in the secretome of the metastatic ovarian cancer. We employed a quantitative glycomics approach based on metabolic stable isotope labeling to compare the differential N-glycosylation of secretome between an ovarian cancer cell line SKOV3 and its high metastatic derivative SKOV3-ip. Intriguingly, among total 17 N-glycans identified, the N-glycans with bisecting GlcNAc were all significantly decreased in SKOV3-ip in comparison to SKOV3. This alteration in bisecting GlcNAc glycoforms as well as its corresponding association with ovarian cancer metastatic behavior was further validated at the glycotransferase level with multiple techniques including real-time PCR, western blotting, transwell assay, lectin blotting and immunohistochemistry analysis. This study illustrated metastasis-related N-glycan alterations in ovarian cancer secretome in vitro for the first time, which is a valuable source for biomarker discovery as well. Moreover, N-glycans with bisecting GlcNAc shed light on the detection of ovarian cancer in early peritoneal metastasis stage which may accordingly improve the prognosis of ovarian cancer patients.
Farnesoid X receptor associates with -catenin and inhibits its activity in hepatocellular carcinoma Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma